Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.
- Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5%
- Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
Palo Alto acquires CyberArk. A new leader in cybersecurity!
US OPEN: Blowout Payrolls Signal Slower Path for Rate Cuts?
Market wrap: Oil gains amid US - Iran tensions 📈 European indices muted before US NFP report
Economic calendar: NFP data and US oil inventory report 💡